Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications

被引:32
作者
Hicks, Angel Mier [1 ]
Chou, Joanne [2 ]
Capanu, Marinela [2 ]
Lowery, Maeve A. [3 ]
Yu, Kenneth H. [3 ]
O'Reilly, Eileen M. [3 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Med, St Lukes Roosevelt Hosp Ctr Program, New York, NY 10029 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
关键词
Denver shunt; Malignant ascites; Performance status; Peritoneal catheter; Teneckoff catheter; QUALITY-OF-LIFE; MALIGNANT ASCITES; PERITONEOVENOUS SHUNTS; PROGNOSTIC-FACTORS; CANCER; DIAGNOSIS; CATHETER; PATHOPHYSIOLOGY; CATUMAXOMAB; PALLIATION;
D O I
10.1016/j.clcc.2016.04.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This was a cohort analysis evaluating patients with pancreatic adenocarcinoma who presented with or developed ascites. Among the 180 patients analyzed, the use of serial paracenteses and indwelling catheters is a common practice to effect symptom palliation. The complication rate was higher in patients with indwelling catheters. Analyzing ascitic fluid and calculating the serum ascites albumin gradient can help attribute the etiology of the ascites and potentially identify which patients may benefit from diuretics or other intervention. Background: Ascites develops in a subset of patients with pancreatic adenocarcinoma (PAC) at presentation or as the disease advances. Limited data exist on the prognostic importance of malignant ascites in PAC. Our hypothesis is that this information will provide an understanding of the natural history and facilitate management decisions. Methods: We conducted a retrospective analysis of 180 patients treated at Memorial Sloan Kettering Cancer Center diagnosed between January 1, 2009 and December 31, 2014, with PAC and with ascites either at presentation or that developed during the disease course. Results: For the 180 patients, the overall survival was 15 months. The time from diagnosis to ascites presentation was 11 months, and the survival time after ascites development was 1.8 months (range, 1.6-2.3 months; 95% confidence interval). Of 62 patients (34%) who had ascitic fluid analyzed, 36 (58%) had positive cytology. Fifty-one (82%) patients had a serum ascites albumin gradient >= 1, and 11 (18%) had serum ascites albumin gradient < 1. Sixty-four (36%) patients had their ascites managed solely by serial paracenteses. A total of 116 patients required a catheter; of these, 108 (93%) had a Tenckhoff catheter, 4 (3%) a Pleurx catheter, 4 (3%) a pigtail catheter, and 1 (1%) a Denver catheter. Eight (7%) patients required 2 catheters to be placed, and in 6 (5%), Tenckhoff catheters had to be removed. The main observed complications were spontaneous bacterial peritonitis in 7 (11%) managed with paracenteses versus 26 (23%) who had a catheter placed, catheter malfunction in 8 (7%), and acute renal failure in 6 (3%). After ascites development, 79 (44%) patients received active anti-cancer therapy, and 101 (56%) patients were managed with supportive care alone. Conclusions: In patients with PAC who presented with or developed ascites, serial paracenteses and indwelling catheters are common methods used for providing symptomatic relief. The complication rate was higher with indwelling catheters, primarily related to infection (eg, bacterial peritonitis). Overall, ascites has a significantly negative prognostic import with a short median survival.
引用
收藏
页码:360 / 368
页数:9
相关论文
共 48 条
  • [1] [Anonymous], CLIN MED DIAGNOSTICS
  • [2] Malignant ascites - New concepts in pathophysiology, diagnosis, and management
    Aslam, N
    Marino, CR
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (22) : 2733 - 2737
  • [3] Pattern and prognostic factors in patients with malignant ascites: a retrospective study
    Ayantunde, A. A.
    Parsons, S. L.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (05) : 945 - 949
  • [4] Malignant ascites: Systematic review and guideline for treatment
    Becker, G
    Galandi, D
    Blum, HE
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (05) : 589 - 597
  • [5] Becker Gerhild, 2007, Cancer Treat Res, V134, P459
  • [6] Radiological insertion and management of peritoneovenous shunt
    Bratby, M. J.
    Hussain, F. F.
    Lopez, A. J.
    [J]. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2007, 30 (03) : 415 - 418
  • [7] Malignant ascites: pathophysiology and treatment
    Cavazzoni, Emanuel
    Bugiantella, Walter
    Graziosi, Luigina
    Franceschini, Maria Silvia
    Donini, Annibale
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (01) : 1 - 9
  • [8] Treatment of Malignant Ascites
    Chung, Michael
    Kozuch, Peter
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2008, 9 (2-3) : 215 - 233
  • [9] Outcomes of Permanent Peritoneal Ports for the Management of Recurrent Malignant Ascites
    Coupe, Nicholas Anthony
    Cox, Keith
    Clark, Katherine
    Boyer, Michael
    Stockler, Martin
    [J]. JOURNAL OF PALLIATIVE MEDICINE, 2013, 16 (08) : 938 - 940
  • [10] Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA
    DeWitt, John
    Yu, Menggang
    Al-Haddad, Mohamad A.
    Sherman, Stuart
    McHenry, Lee
    LeBlanc, Julia K.
    [J]. GASTROINTESTINAL ENDOSCOPY, 2010, 71 (02) : 260 - 265